AGLARIS: The First Fully-automated Bioreactor for Large Scale Human Stem Cell Production through an Iterative Process.

Projektinformationen

AGLARIS

ID Finanzhilfevereinbarung: 729499

DOI 10.3030/729499

Abgeschlossenes Projekt

EK-Unterschriftsdatum 4 Mai 2016

Startdatum 1 Juni 2016

Enddatum 30 September 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

AGLARIS LIMITED
United Kingdom

Ziel

In order to meet the expanding market for human stem cells (HSCs) in cell therapy, automated, cost-effective, large-scale manufacturing processes are required. AGLARIS Project is centered in the market launch of the patented AGLARIS BIOREACTOR for large-scale HSCs production, which perfectly meets the requirements for cell-based therapeutic products. Current bioreactors for HSCs producers consist in attempts to adapt bioreactors derived from traditional bioprocesses, but its use has not been widespread as they are not optimized for HSCs production. The automation level of bioreactors is limited to an initial quantity of 20M cells. As the cell sample from biopsies contains 0.5-1M cells, a previous manual cultivation is always required to reach the minimum quantity. This step affects cell quality. AGLARIS operates with the quantity of cells coming directly from biopsy, completely eliminating the manual pre-cultivation requirement. Moreover, current Bioreactors are limited to 300M cells per cell batch. The common are based on hollow-fibers as the substrate in which cells are anchored for growing. Once they reach its maximum capacity, cells need to be detached by using chemical and enzymatic reagents. AGLARIS operates in an iterative manner reaching 5000M cells without dividing the cultivation process in several batches. It is based on microcarriers which allows cell detachment by a simply small variation of temperature, avoiding adverse side effects. Additionally, for a complete disease management, the production of 600M cells on average is required. When produced manually, the cultivation of 600M cells can reach 9.347€, and by using hollow-fiber Bioreactors 15.643€. AGLARIS optimized culture process produces cell yields with the correct quality while using minimal amounts of expensive reagents, allowing the price to decrease to 1.015€ per 600 M of cells, meaning that costs will be reduced by up to 91% on average.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• engineering and technology › mechanical engineering › manufacturing engineering
• engineering and technology › environmental biotechnology › bioremediation › bioreactors
• medical and health sciences › medical biotechnology › cells technologies › stem cells
• engineering and technology › electrical engineering, electronic engineering, information engineering › electronic engineering › sensors

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

AGLARIS LIMITED

• Netto-EU-Beitrag: € 50 000,00
• Adresse: STEVENAGE BIOSCIENCE CATALYST, F30, GUNNELS WOOD R ; SG1 2FX Stevenage ; Vereinigtes Königreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  East of England › Bedfordshire and Hertfordshire › Hertfordshire
• Region: East of England › Bedfordshire and Hertfordshire › Hertfordshire
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00